DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge

Vaccine

Volumn 29, Issue 44, 2011, Pages 7740-7746

  Lu, Yu Chun ^a   Li, Min Chen ^a   Chen, Yi Min ^a   Chu, Chun Yen ^b   Lin, Shuen Fuh ^a   Yang, Wen Jen ^a  

^a NATIONAL UNIVERSITY OF KAOHSIUNG   (Taiwan)

^b NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Actinobacillus pleuropneumoniae; ApfA; DNA vaccine; Type IV pilin

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; PILIN; STRUCTURAL PROTEIN;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC MANIPULATION; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PORCINE PLEUROPNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; TH1 CELL; TH2 CELL;

ACTINOBACILLUS INFECTIONS; ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FIMBRIAE PROTEINS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PLEUROPNEUMONIA; SURVIVAL ANALYSIS; TH1 CELLS; TH2 CELLS; VACCINES, DNA;

EID: 80053587807     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.127     Document Type: Article

References (37)

1. Bosse J.T., Janson H., Sheehan B.J., Beddek A.J., Rycroft A.N., Kroll J.S., et al. Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes Infect 2002, 4(2):225-235.
2. Dom P., Haesebrouck F., Ducatelle R., Charlier G. In vivo association of Actinobacillus pleuropneumoniae serotype 2 with the respiratory epithelium of pigs. Infect Immun 1994, 62(4):1262-1267.
3. Torremorell M., Pijoan C., Janni K., Walker R., Joo H.S. Airborne transmission of Actinobacillus pleuropneumoniae and porcine reproductive and respiratory syndrome virus in nursery pigs. Am J Vet Res 1997, 58(8):828-832.
4. Chiers K., Donne E., Van Overbeke I., Ducatelle R., Haesebrouck F. Actinobacillus pleuropneumoniae infections in closed swine herds: infection patterns and serological profiles. Vet Microbiol 2002, 2(854):343-352.
5. Dubreuil J.D., Jacques M., Mittal K.R., Gottschalk M. Actinobacillus pleuropneumoniae surface polysaccharides: their role in diagnosis and immunogenicity. Anim Health Res Rev 2000, 1(2):73-93.
6. Blackall P.J., Klaasen H.L., van den Bosch H., Kuhnert P., Frey J. Proposal of a new serovar of Actinobacillus pleuropneumoniae: serovar 15. Vet Microbiol 2002, 84(1-2):47-52.
7. Frey J. Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends Microbiol 1995, 3(7):257-261.
8. Rogers R.J., Eaves L.E., Blackall P.J., Truman K.F. The comparative pathogenicity of four serovars of Actinobacillus (Haemophilus) pleuropneumoniae. Aust Vet J 1990, 67(1):9-12.
9. Inzana T.J., Ma J., Workman T., Gogolewski R.P., Anderson P. Virulence properties and protective efficacy of the capsular polymer of Haemophilus (Actinobacillus) pleuropneumoniae serotype 5. Infect Immun 1988, 56(8):1880-1889.
10. Bandara A.B., Lawrence M.L., Veit H.P., Inzana T.J. Association of Actinobacillus pleuropneumoniae capsular polysaccharide with virulence in pigs. Infect Immun 2003, 71(6):3320-3328.
11. Udeze F.A., Latimer K.S., Kadis S. Role of Haemophilus pleuropneumoniae lipopolysaccharide endotoxin in the pathogenesis of porcine haemophilus pleuropneumonia. Am J Vet Res 1987, 48(5):768-773.
12. Rapp V.J., Ross R.F. Antibody response of swine to outer membrane components of Haemophilus pleuropneumoniae during infection. Infect Immun 1986, 54(3):751-760.
13. Shakarji L., Mikael L.G., Srikumar R., Kobisch M., Coulton J.W., Jacques M., et al. Fhua and HgbA, outer membrane proteins of Actinobacillus pleuropneumoniae: their role as virulence determinants. Can J Microbiol 2006, 52(4):391-396.
14. Baltes N., Tonpitak W., Gerlach G.F., Hennig-Pauka I., Hoffmann-Moujahid A., Ganter M., et al. Actinobacillus pleuropneumoniae iron transport and urease activity: effects on bacterial virulence and host immune response. Infect Immun 2001, 69(1):472-478.
15. Beddek A.J., Sheehan B.J., Bosse J.T., Rycroft A.N., Kroll J.S., Langford P.R. Two TonB systems in Actinobacillus pleuropneumoniae: their roles in iron acquisition and virulence. Infect Immun 2004, 72(2):701-708.
16. Kamp E.M., Stockhofe-Zurwieden N., van Leengoed L.A., Smits M.A. Endobronchial inoculation with Apx toxins of Actinobacillus pleuropneumoniae leads to pleuropneumonia in pigs. Infect Immun 1997, 65(10):4350-4354.
17. Hensel A., Stockhofe-Zurwieden N., Petzoldt K., Lubitz W. Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge. Infect Immun 1995, 63(8):3048-3053.
18. Tumamao J.Q., Bowles R.E., van den Bosch H., Klaasen H.L., Fenwick B.W., Storie G.J., et al. Comparison of the efficacy of a subunit and a live streptomycin-dependent porcine pleuropneumonia vaccine. Aust Vet J 2004, 82(6):370-374.
19. Tumamao J.Q., Bowles R.E., van den Bosch H., Klaasen H.L., Fenwick B.W., Blackall P.J. An evaluation of the role of antibodies to Actinobacillus pleuropneumoniae serovar 1 and 15 in the protection provided by sub-unit and live streptomycin-dependent pleuropneumonia vaccines. Aust Vet J 2004, 82(12):773-780.
20. Craig L., Pique M.E., Tainer J.A. Type IV pilus structure and bacterial pathogenicity. Nat Rev Microbiol 2004, 2(5):363-378.
21. Lepper A.W., Atwell J.L., Lehrbach P.R., Schwartzkoff C.L., Egerton J.R., Tennent J.M. The protective efficacy of cloned Moraxella bovis pili in monovalent and multivalent vaccine formulations against experimentally induced infectious bovine keratoconjunctivitis (IBK). Vet Microbiol 1995, 45:129-138.
22. Walduck A.K., Opdebeeck J.P. Effect of adjuvants on antibody responses of sheep immunised with recombinant pili from Dichelobacter nodosus. Aust Vet J 1996, 74(6):451-455.
23. Scavone P., Sosa V., Pellegrino R., Galvalisi U., Zunino P. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins. Microbes Infect 2004, 6(9):853-860.
24. Alves A.M., Lasaro M.O., Almeida D.F., Ferreira L.C. DNA immunisation against the CFA/I fimbriae of enterotoxigenic Escherichia coli (ETEC). Vaccine 2000, 19(7-8):788-795.
25. Fernandes P.J., Guo Q., Waag D.M., Donnenberg M.S. The type IV pilin of Burkholderia mallei is highly immunogenic but fails to protect against lethal aerosol challenge in a murine model. Infect Immun 2007, 75(6):3027-3032.
26. Ramjeet M., Deslandes V., Goure J., Jacques M. Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies. Anim Health Res Rev 2008, 9:25-45.
27. Stevenson A., Macdonald J., Roberts M. Cloning and characterisation of type 4 fimbrial genes from Actinobacillus pleuropneumoniae. Vet Microbiol 2003, 92(1-2):121-134.
28. Shao M., Wang Y., Wang C., Guo Y., Peng Y., Liu J., et al. Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice. Acta Vet Scand 2010, 52:52.
29. Chiang C.H., Huang W.F., Huang L.P., Lin S.F., Yang W.J. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model. Vaccine 2009, 27(34):4565-4570.
30. Oldfield N.J., Donovan E.A., Worrall K.E., Wooldridge K.G., Langford P.R., Rycroft A.N., et al. Identification and characterization of novel antigenic vaccine candidates of Actinobacillus pleuropneumoniae. Vaccine 2008, 26(11):1942-1954.
31. Goethe R., Gonzales O.F., Lindner T., Gerlach G.F. A novel strategy for protective Actinobacillus pleuropneumoniae subunit vaccines: detergent extraction of cultures induced by iron restriction. Vaccine 2000, 19(7-8):966-975.
32. Liao C.W., Chiou H.Y., Yeh K.S., Chen J.R., Weng C.N. Oral immunization using formalin-inactivated Actinobacillus pleuropneumoniae antigens entrapped in microspheres with aqueous dispersion polymers prepared using a co-spray drying process. Prev Vet Med 2003, 61(1):1-15.
33. van Oirschot J.T. Vaccination in food animal populations. Vaccine 1994, 12(5):415-418.
34. Salonius K., Simard N., Harland R., Ulmer J.B. The road to licensure of a DNA vaccine. Curr Opin Investig Drugs 2007, 8(8):635-641.
35. Egerton J.R., Cox P.T., Anderson B.J., Kristo C., Norman M., Mattick J.S. Protection of sheep against footrot with a recombinant DNA-based fimbrial vaccine. Vet Microbiol 1987, 14(4):393-409.
36. Park J.H., Kim S.J., Oem J.K., Lee K.N., Kim Y.J., Kye S.J., et al. Enhanced immune response with foot and mouth disease virus VP1 and interleukin-1 fusion genes. J Vet Sci 2006, 7(3):257-262.
37. Shin S.J., Shin S.W., Kang M.L., Lee D.Y., Yang M.S., Jang Y.S., et al. Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. J Vet Sci 2007, 8(4):383-392.